EBS
Emergent BioSolutions Inc.
EBS lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
EBS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Strong | |
| Weak |
EBS's cash flow is currently strong, and its revenue is stable, but its profitability and balance sheet are weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
EBS PE Valuation
EBS has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 16x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
EBS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
EBS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
EBS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.38 | — |
| Q3 2026 | -$5.01 | -450% |
| Q2 2026 | -$3.46 | -234% |
| Q1 2026 | -$0.19 | +$2.39 |
| Q4 2025 | $0.93 | +$4.53 |
| Q3 2025 | $1.43 | +$5.48 |
| Q2 2025 | $2.58 | +$13.77 |
| Q1 2025 | -$2.58 | +$8.38 |
| Q4 2024 | -$3.60 | +$11.18 |
EBS has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
EBS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $110M | -52% |
| Q2 2026 | $234.3M | +66% |
| Q1 2026 | $156.1M | -30% |
| Q4 2025 | $148.7M | -24% |
| Q3 2025 | $231.1M | -21% |
| Q2 2025 | $140.9M | -45% |
| Q1 2025 | $222.2M | -26% |
| Q4 2024 | $194.7M | -30% |
EBS's revenue has slid since its 2021 peak: $110M last quarter, down 52% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -34% | -67 points |
| Q2 2026 | -53% | -55 points |
| Q1 2026 | 6.7% | -16 points |
| Q4 2025 | -19% | -14 points |
| Q3 2025 | 33% | +11 points |
| Q2 2025 | 1.1% | +81 points |
| Q1 2025 | 22% | +9.2 points |
| Q4 2024 | -4.9% | +11 points |
EBS's operating margin was −34% last quarter, down 67 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over EBS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over EBS on profitability, with a higher operating margin.
EBS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $96.8M | +$102.5M |
| Q2 2026 | $54M | -48% |
| Q1 2026 | -$36.2M | -$21.4M |
| Q4 2025 | $73.8M | +$155.4M |
| Q3 2025 | -$5.7M | -104% |
| Q2 2025 | $103.5M | +141% |
| Q1 2025 | -$14.8M | +$58.6M |
| Q4 2024 | -$81.6M | -494% |
EBS still generates free cash flow, though less than at its 2021 peak: $188M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over EBS on cash flow, with more consistent year-over-year improvement.
EBS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -300K shares |
| 1 year | -9.2% | -5.2M shares |
| 3 years | -1% | -500K shares |
| 5 years | -4.5% | -2.4M shares |
| Available history | -2.1% | -1.1M shares |
EBS has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100,000 |
| Q2 2026 | $9M |
| Q1 2026 | $9M |
| Q4 2025 | $9.1M |
| Q3 2025 | $8.9M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
EBS spent $27M buying back its own shares over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
EBS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 15.6x | High |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 67.1x | High |
| Q4 2024 | 5,642.0x | High |
| Q3 2021 | 1.1x | Healthy |
EBS's net debt is about 16 years of its operating earnings (EBITDA), up from 1.9 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over EBS on leverage, with a lower net debt burden relative to earnings.
EBS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 56.9 | Neutral |
EBS's weekly RSI is 42 (neutral) and its Stochastic is 57 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
EBS PE vs Healthcare Sector
| Metric | EBS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
EBS has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
EBS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.44 | 8.5% below |
| 20 week MA | $6.48 | 9.1% below |
| 50 week MA | $8.41 | 30% below |
| 100 week MA | $8.14 | 28% below |
| 200 week MA | $7.37 | 20% below |
EBS is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
EBS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.0 | $93.8 | +74% |
| 2021 | $93.8 | $45.5 | -51% |
| 2022 | $45.5 | $11.0 | -76% |
| 2023 | $11.0 | $2.40 | -78% |
| 2024 | $2.40 | $8.27 | +245% |
| 2025 | $8.27 | $12.4 | +50% |
| 2026 YTD | $12.4 | $5.89 | -53% |
EBS's yearly returns have swung widely, from +245% in 2024 to −78% in 2023. It's down 53% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over EBS on returns for 2026, with the stronger performance.